Latest Life Sciences News

Page 3 of 21
Biotron has appointed Glenn Gilbert as chief executive and executive director, bringing more than two decades of pharmaceutical, medical device and diagnostics experience to the company’s SedRx and antiviral programs. His package combines a $250,000 salary with up to 100 million performance-based options and $230,000 in milestone-linked cash bonuses.
Victor Sage
Victor Sage
14 Oct 2026
Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.
Ada Torres
Ada Torres
8 Oct 2026
Trajan Scientific and Medical (ASX:TRJ) says FY27 has begun with improving revenue, quarterly nEBITDA of about A$3.5 million and a A$1.6 million reduction in net debt. The company expects mid-single-digit organic revenue growth and double-digit nEBITDA growth for the year, although its latest quarterly figures remain unaudited.
Victor Sage
Victor Sage
8 Oct 2026
Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.
Victor Sage
Victor Sage
30 Sept 2026
AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.
Victor Sage
Victor Sage
30 Sept 2026
AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.
Victor Sage
Victor Sage
28 Sept 2026
AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.
Victor Sage
Victor Sage
28 Sept 2026
Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.
Victor Sage
Victor Sage
22 Sept 2026
Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.
Ada Torres
Ada Torres
4 Sept 2026
Vitrafy Life Sciences has secured its first US cell and gene therapy foothold by deploying its cryopreservation technology at Charter Medical's Innovation Hub, signalling a strategic expansion into a high-value biopharma segment.
Ada Torres
Ada Torres
2 Sept 2026
BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.
Victor Sage
Victor Sage
31 Aug 2026

Browse the archive

Full archive